Value-Based Arrangements May Be More Prevalent Than Assumed
We surveyed biopharmaceutical manufacturers and payers to understand the prevalence and characteristics of value-based payment arrangements, as well as their implementation obstacles and success factors.
Impact of Hepatitis C Virus and Insurance Coverage on Mortality
The Medicaid population has significantly higher hepatitis C virus (HCV) prevalence and mortality rates than patients with private insurance. These data must be considered when policy makers assess providing additional support to Medicaid programs for HCV elimination.
Process Reengineering and Patient-Centered Approach Strengthen Efficiency in Specialized Care
Improving efficiency is complex and requires a multimodal approach. Health information systems, patient feedback, and multidisciplinary teams are components that can improve clinical processes.
Validating a Method to Assess Disease Burden From Insurance Claims
When we weighted health insurance claims with a disease burden score, we were able to generate valid estimates of disability-adjusted life-years.
Does Comparing Cesarean Delivery Rates Influence Women’s Choice of Obstetric Hospital?
This randomized controlled trial finds that a hospital cesarean delivery rate comparison tool affects women’s perceptions but not where they choose to deliver.
Performance of the Adapted Diabetes Complications Severity Index Translated to ICD-10
We present an International Classification of Diseases, Tenth Revision (ICD-10) translation of the adapted Diabetes Complications Severity Index and show its performance in predicting hospitalizations, mortality, and healthcare-associated costs.
Are Value-Based Incentives Driving Behavior Change to Improve Value?
Value-based payment is promoting care delivery transformation among California physician organizations, although the initial focus has been on controlling hospital costs and redesigning primary care.
The Drug Price Iceberg: More Than Meets the Eye
January 30th 2019When it comes to the political iceberg of drug prices, there is more than meets the eye. Policies that reduce prices but do not lower consumers’ out-of-pocket costs will not address the main challenge facing most Americans.